Next Article in Journal
Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
Next Article in Special Issue
Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives
Previous Article in Journal
Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
Previous Article in Special Issue
Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy
Open AccessReview

Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future

1
Department of Medical Oncology, Hôpital Saint-Antoine, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), F-75012 Paris, France
2
Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1990; https://doi.org/10.3390/cancers12071990
Received: 15 June 2020 / Revised: 10 July 2020 / Accepted: 17 July 2020 / Published: 21 July 2020
(This article belongs to the Special Issue Adjuvant Chemotherapy for Colorectal Cancer)
Immune checkpoint inhibitors (ICI) have reshaped therapeutic strategies for cancer patients. The development of ICI for early stage colorectal cancer is accompanied by specific challenges: (i) the selection of patients who are likely to benefit from these treatments, i.e., patients with tumors harboring predictive factors of efficacy of ICI, such as microsatellite instability and/or mismatch repair deficiency (MSI/dMMR), or other potential parameters (increased T cell infiltration using Immunoscore® or others, high tumor mutational burden, POLE mutation), (ii) the selection of patients at risk of disease recurrence (poor prognostic features), and (iii) the choice of an accurate clinical trial methodological framework. In this review, we will discuss the ins and outs of clinical research of ICI for early stage MSI/dMMR CC patients in adjuvant and neoadjuvant settings. We will then summarize data that might support the development of ICI in localized colorectal cancer beyond MSI/dMMR. View Full-Text
Keywords: stage III; microsatellite instability; mismatch repair deficiency; oxaliplatin; immunoscore stage III; microsatellite instability; mismatch repair deficiency; oxaliplatin; immunoscore
MDPI and ACS Style

Cohen, R.; Shi, Q.; André, T. Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. Cancers 2020, 12, 1990.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop